Despite this, investors seem to have made up their one-track mind. Eli Lilly’s P/E ratio is more than double that of Novo ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The future of the weight loss market might not revolve around GLP-1 drugs.

Novo Nordisk’s stock declined 12% in the past month. Wegovy's sales growth stays under pressure. Read why I'm neutral on NVO ...

Novo Nordisk , whose global profile has risen along with demand for its Wegovy weight-loss drug, is bolstering operations in ...

NEW YORK (Reuters) -U.S. Senator Elizabeth Warren has asked antitrust regulators to scrutinize a $16.5 billion deal in which ...

WeightWatchers said on Tuesday it would offer a compounded version of Novo Nordisk's popular obesity drug Wegovy as part of ...

Danish biotech Zealand Pharma is targeting the “next generation” of weight loss drugs as competitors pile into a market ...

Novo Nordisk (NVO) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the ...

Jim Cramer believes Uranium Energy Corp. is going higher, thanks to a recent acquisition deal. Novo Nordisk faces antitrust concerns while Halliburton gets a Buy rating from BofA Securities.

Chinese insulin maker Gan & Lee Pharmaceuticals is wading into the obesity world with an injectable GLP-1 agonist that beat Novo Nordisk's Ozempic (semaglutide) at lowering glycated hemoglobin (HbA1c) ...